NCT00472043View on ClinicalTrials.gov

PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma

PHASE3CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 1, 2000

Primary Completion Date

September 30, 2002

Study Completion Date

September 30, 2002

Conditions
Basal Cell Carcinoma
Interventions
DRUG

PDT with Metvix 160 mg/g cream

DRUG

Placebo

Trial Locations (7)

2050

Dept. of Dermatology, Royal Prince Alfred Hospital, Camperdown

2170

Dermatology Centre, Liverpool

2217

Dermatology Dept., St. George Hospital, Kogarah

3065

Department of Dermatology, St. Vincent's Hospital Melbourne, Fitzroy

4217

Dr. Michael Freeman, Benowa

6160

Fremantle Dermatology, Fremantle

Unknown

Dermatology Dept., Princess Alexandra Hospital, Woolloongabba

Sponsors

Lead Sponsor

Galderma R&D
All Listed Sponsors
lead

Galderma R&D

INDUSTRY

NCT00472043 - PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma | Biotech Hunter | Biotech Hunter